The White House dropped the 250-page 100-day supply chain review on Tuesday 8 June 2021, and if you’re importing anything that touches rare earths, lithium, cobalt, nickel, tungsten, antimony, or an active pharmaceutical ingredient from China, you need to read it this week rather than scanning the press release. Executive Order 14017 commissioned this work in February. What came back is an unvarnished, department-by-department catalogue of just how deep US dependence on Chinese chemistry and Chinese minerals actually runs.
The four focus areas were semiconductors, large-capacity batteries, critical minerals and materials, and pharmaceuticals and APIs. Every one of those sections reads the same way: the US relies on China for the critical mineral inputs, the midstream processing, the specialty chemical intermediates, or the finished API. In many cases, all four. The report names the vulnerabilities, counts the single-source dependencies, and tells you the administration is serious about structural intervention.
What the report does not tell you is that any of this gets fixed before 2025. Tax credits, DPA Title III allocations, and stockpile build-outs take years. Your 2021, 2022, and most of 2023 buying still depends on the same Chinese supply chain that this report flags as a national security liability. That tension is exactly where chemical importers need to plan.
The Four Sectors and the Chemistry That Sits Inside Each One
Every one of the four focus sectors in the report is chemistry-heavy once you scratch the surface. The headlines talked about semiconductors and batteries. Chemical importers need to look at the intermediates that make those end products possible.
Semiconductors. The press talked about chip fabs. The chemistry underneath is photoresists, etchants, specialty gases, CMP slurries, wet chemicals, and ultra-high-purity precursors. Japanese and Korean producers dominate several of these segments, but Chinese producers have been climbing the specialty gas and electronic chemical ladder aggressively. The report flags the fragility of the electronic chemicals supply chain and the high concentration in Asia.
Large-capacity batteries. This is the loudest section. Lithium, cobalt, nickel, manganese, and graphite are the headline minerals. The chemistry is lithium carbonate and lithium hydroxide for cathode, cobalt sulfate and nickel sulfate for NMC and NCA cathodes, and a long tail of electrolyte salts including lithium hexafluorophosphate (LiPF6) and fluorinated additives. China refines roughly 60% of the world’s lithium, 65% of cobalt, 35% of nickel, and produces the overwhelming majority of cathode and anode active materials globally. The report flags this as the single biggest structural dependence across the four sectors.
Critical minerals. The Department of the Interior and USGS contributions name 50 minerals as critical. Rare earth elements, where China controls roughly 60% of mining and over 85% of separation and refining capacity, get the most attention. Neodymium, praseodymium, dysprosium, and terbium for permanent magnets are specifically called out. Tungsten, antimony, gallium, germanium, and graphite also make the list with explicit China-concentration numbers.
Pharmaceuticals and APIs. The HHS contribution is the one that should worry anyone importing pharmaceutical intermediates. Roughly 80% of API manufacturing for the US market now takes place outside the US, with China and India dominating. The report flags specific categories including generic antibiotics, acetaminophen precursors, vitamin intermediates, and a long list of specialty synthesis intermediates where China is effectively sole-source at commercial scale.
The China-Dependence Numbers Pulled Straight From the Report
The report is dense with statistics. Here’s the short list that chemical importers need to absorb, product by product, source-concentration percentage by percentage.
| Mineral or Chemical | Chinese Share of Global Supply or Refining | US Import Reliance | Primary Use |
|---|---|---|---|
| Rare earth elements (refined) | ~85% | 100% | Permanent magnets, catalysts, polishing |
| Lithium (refined) | ~60% | ~50% | Battery cathode, glass, pharmaceuticals |
| Cobalt (refined) | ~65% | ~76% | Battery cathode, aerospace alloys |
| Graphite (natural, refined) | ~75% | 100% | Battery anode, refractories |
| Tungsten (refined) | ~80% | ~85% | Cutting tools, filaments, catalysts |
| Antimony (mined and refined) | ~75% | ~85% | Flame retardants, lead-acid batteries |
| Gallium (refined) | ~95% | 100% | Semiconductors, LEDs, photovoltaics |
| Active Pharmaceutical Ingredients (generic) | ~40% to 45% | ~72% (with India share) | All therapeutic categories |
| Acetaminophen intermediates | ~65% | ~90% | OTC and prescription analgesics |
| Vitamin C and vitamin intermediates | ~80% | ~95% | Nutraceuticals, food fortification |
Read those numbers twice. “100% import reliance” means the US produces zero commercial quantity of the product. For rare earths, graphite, and gallium, there isn’t a domestic supplier you can rotate to even if you wanted to pay a premium. The report doesn’t soften any of this.
What the Report Actually Recommends and Why None of It Lands Before 2023
Every one of the four agency sections concludes with recommendations. Tax credits for domestic production, Defense Production Act Title III allocations, strategic stockpile expansions, R&D funding for alternative chemistries, friend-shoring partnerships with allied producers, and in some cases outright tariff or export-control interventions against imports that undermine domestic investment.
The timeline on every one of these is multi-year at best. DPA Title III allocations for critical minerals take 18 to 24 months from announcement to the first drop of product leaving a domestic facility. Rare earth separation capacity in the US is being built out at Mountain Pass and via MP Materials’ planned Texas facility, but at-scale separation of heavy rare earths domestically is a 2024 to 2025 story, not a 2022 story. API reshoring requires FDA-qualified manufacturing, which itself is a 24 to 36 month pathway for any new facility.
What that means for your buying programme is that the period between today, 10 June 2021, and realistically late 2024 is going to be a transition window where the policy environment is actively hostile to Chinese supply while the practical alternatives are either more expensive, limited in capacity, or not yet operational. You need to buy through that window.
The Policy Risk Layer That Now Sits On Top of Every Shipment
The supply chain review does two things to your risk model even before any specific new policy gets enacted. First, it formally establishes in federal government documentation that certain categories of Chinese chemical imports are a national security vulnerability. That framing, once it’s in a White House report, doesn’t go away. It sits underneath the next round of export controls, the next CFIUS review, and the next tariff action.
Second, it gives every federal agency with authority over your supply chain a citation they can point to when they act. CBP can tighten enforcement on specific HTS codes. The Commerce Department’s Bureau of Industry and Security can expand entity list coverage. The Defense Department can require prime contractors to declare Chinese content in critical minerals and chemistries. Treasury’s CFIUS reviews of Chinese investments in US chemistry become faster to reject. All of those tools were available before 8 June. Now they have an administration-signed framework telling agencies when to use them.
For chemical importers, the practical consequence is that compliance costs are rising and will continue to rise. Due diligence on Chinese suppliers needs to include ownership structure, end-use declarations, and in some categories anti-forced-labour documentation under the Uyghur Forced Labor Prevention Act framework (the UFLPA hasn’t been signed yet as of June 2021, but the trajectory is clear). Shipments that used to clear CBP in a day might now sit for additional documentation requests. The ones that sit longest are the ones touching anything on the critical minerals list.
Landed Cost on a Critical Minerals Shipment With 2021 Freight and Policy Overhead
Here’s what a realistic shipment of lithium carbonate for a US battery precursor customer looks like on a landed cost basis in June 2021, factoring in the compliance overhead that’s genuinely showing up on invoices.
Assume 40 MT of battery-grade lithium carbonate, 99.5% purity, packaged in 25-kg bags inside a 20-foot dry container. FOB Qingdao at current May and early June spot levels.
| Cost Component | Per MT | Per 40-MT Container Shipment |
|---|---|---|
| FOB Qingdao, battery-grade lithium carbonate 99.5% | $14,200 | $568,000 |
| Chinese export inspection (SGS or Bureau Veritas) | $35 | $1,400 |
| Inland China freight to port | $30 | $1,200 |
| Ocean freight, Qingdao to US West Coast | $280 | $11,200 |
| Section 301 List 3 duty at 25% | $3,550 | $142,000 |
| MPF and HMF | $28 | $1,120 |
| Enhanced CBP documentation and compliance brokerage | $55 | $2,200 |
| US inland rail and trucking to Midwest customer | $110 | $4,400 |
| Total landed cost | $18,288 | $731,520 |
The lithium carbonate itself is up 108% from November 2020. The Section 301 25% on this HTS subheading adds $3,550 per MT that the supply chain review has now effectively locked in place. The enhanced compliance brokerage line is small in isolation but real, and it’s growing every quarter as CBP tightens documentation requirements on critical minerals entries.
Run that same calculation on any of the critical minerals in the June 8 report, plug in your own volume, and you’ll see the same dynamic: the commodity has moved, the tariff is sticky, and the compliance costs are climbing. None of those three numbers are going down in 2021 or 2022.
What the Next 90 Days of Policy Look Like
Watch three specific policy tracks over the next quarter. The administration has already signalled a Trade Strike Force led by USTR that will identify specific Section 301, Section 232, and Section 201 actions coming out of the review. Expect announcements in Q3 on narrow, product-specific tariff or export-control actions covering rare earth magnets, graphite anode materials, and possibly specific API categories.
The Senate’s US Innovation and Competition Act, which passed on 8 June with the supply chain review timing clearly coordinated, includes roughly $52 billion for semiconductor manufacturing and R&D. Final conference with the House and a likely presidential signing in Q4 will put specific programmes and tax credits into motion. The downstream effect on electronic chemicals demand within 18 months is material.
On the pharmaceutical side, FDA and HHS are expected to push specific incentives for API reshoring through 2021 into 2022. Expect proposed rules on essential medicines sourcing, possibly including minimum domestic content thresholds for federal procurement of generic drugs. Any importer handling pharmaceutical intermediates should be in contact with their customers’ regulatory teams this quarter.
What to Do This Week, Tied to Specific Numbers From the Report
The 85% Chinese rare earth refining share is not going to be cracked by any action taken in 2021. If you import neodymium-iron-boron magnets, rare earth polishing compounds, or rare-earth-containing catalysts, build your 2022 procurement around the assumption that Chinese supply is still your primary source with higher compliance overhead. Map your HTS exposure against the agencies the report flagged and document your due diligence against each supplier this month.
The 100% import reliance on graphite and gallium means that if your products touch either, you have zero domestic rotation option for the next 24 months. Lock in volume commitments with your Chinese suppliers for 12 to 18 months out where the market will let you, and accept higher forward prices as insurance against further commodity moves or trade action.
For pharmaceutical intermediate importers, the 72% combined India-China reliance figure is the one that will drive FDA action. If your products are in therapeutic categories the report called out specifically, including antibiotics, analgesics, and essential generics, expect heightened FDA inspection of foreign facilities, longer DMF review cycles, and in some cases procurement preferences in federal contracts that favour non-Chinese API. Start the conversation with your Chinese suppliers now about dual-sourcing through Indian or European facilities where available.
The supply chain review is a signal, not a fix. The signal says the policy environment is moving against Chinese concentration. The fix takes five years. You’re going to buy Chinese through most of the fix. Plan accordingly.